glp-1 and dpp4 Mechanism of action for GIP, analogues inhibitors in GLP-1 vs DPP-4 Meds: Which

Start Your Weight Loss Path Today Take the first step toward a healthier future

The Medicare Bridge program is a temporary demonstration project that runs from July of this year through December 2027 that provides people over 65 and certain disabled individuals access to select glucagon-like peptide-1 agonist weight loss medications, including Zepbound (tirzepatide), Foundayo (orforglipron) and Wegovy (semaglutide)

Since these medications promote weight loss, a person's menstrual cycles may also become more regular as a result

Cellular stress response pathways may be involved, though mechanisms need more study